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Abstract. The aim of the study was to measure the 
concentrations o f  plasma homocysteine in p rem eno­
pausal and postmenopausal women, and to examine a 
possible relationship between plasma homocysteine 
and oestrogen status. Homocysteine metabolism was 
studied by a standardized oral methionine loading 
test, and oestrogen status was assessed by the 
measurement o f  serum 17/3-oestradiol. Forty-six pre­
menopausal and 26 postmenopausal healthy women 
without a history o f  vascular disease or adverse preg­
nancy outcome were recruited by public advertise­
ment. The main outcome measures were the concen­
trations of fasting and postmethionine plasma h o m o ­
cysteine, and serum 17/3-oestradiol. Fasting plasma 
homocysteine concentrations (mean ±  SD) were sig­
nificantly higher in postmenopausal women as coin- 
pared to premenopausal women (12 ±  4 /¿mol L “ 1 
and 10 ±  3 / imol L ” 1, respectively) as well as post- 
methionine plasma homocysteine concentrations 
(46 ± 16 //mol L -1 and 32 ±  9 /¿mol L ' 1, respec­
tively). In premenopausal women, postmethionine 
plasma homocysteine was negatively and significantly 
correlated to serum 17/3-oestradiol (r =  — 0-34). It is 
concluded that plasma homocysteine concentrations, 
both fasting and after methionine loading, are  signifi­
cantly higher in postmenopausal women than  in pre­
menopausal women. In premenopausal women, the 
higher concentrations o f  serum 17/3-oestradiol may 
account in part  for the lower concentrations o f  p o s t ­
methionine plasma homocysteine.
Keywords. Homocysteine, menopause, oestradiol, 
vitamins.
Introduction
Homocysteine is a thiol-containing amino acid tha t
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results from  the déméthylation o f  methionine. H o m o ­
cysteine is metabolized by transsu lfura t ion  via 
cystathionine to cysteine or by rem ethyla tion  to 
methionine. The conversion to cystathionine is ca ta­
lysed by the enzyme cystathionine /3-synthase in a 
reaction requiring pyridoxal-5 '-phosphate  (PLP, an 
active form o f  vitamin B6) as a cofactor. In  the 
remethylation o f  homocysteine to methionine,  the 
methyl group is donated  by either 5-methyltetrahy- 
drofolate, requiring methylcobaiamin as a cofactor, 
o r  betaine [1],
Homocysteine in b lood is mainly b o u n d  in disul­
fides to proteins and  to cysteine. A m in o r  fraction 
constitutes o f  reduced homocysteine and  the disulfide 
homocysteine—homocysteine (homocystine). Tota l  
homocysteine is defined as the sum o f  all hom ocys­
teine species liberated by reduction [2].
Hyperhomocysteinaemia, i.e. the mild elevation o f  
homocysteine in blood, is a well-established risk 
factor of p rem ature  vascular disease [3,4]. Recently, 
we have reported  significantly elevated concentrations 
o f  p lasm a homocysteine in w om en with unexplained 
recurrent early pregnancy loss or a neural tube defect- 
affected pregnancy [5,6]. Hyperhom ocyste inaem ia  
may also be a risk factor in wom en who have suffered 
from placental ab rup t ion  [7].
There are several reports  indicating that  blood 
homocysteine concentra tions determined as homocys- 
teine-cysteine mixed disulfide and  hom ocystine  [8 -  
10], p ro te in -bound  homocyst(e)ine [11], o r  total 
homocysteine [12-16] are lower in w om en  as com ­
pared to men. Furtherm ore ,  in p rem enopausa l  
women the serum concentrations o f  ho m o cy s te in e -  
cysteine mixed disulfide and  hom ocystine  were 
dem onstra ted  to be significantly lower th an  in pos t­
m enopausal  w om en [9,10]. It was p roposed  that a 
uniquely efficient methionine m etabolism  may 
account for the lower incidence o f  vascular disease 
in wom en before m enopause  [9]. In con tras t ,  it was 
recently reported  th a t  the p lasm a concentra t ions  o f  
free and  total homocysteine are a lm ost  similar in 
w om en and  men, and  independent  o f  m enopausa l  
status [17]. The aim o f  the present  study was to
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measure the concentrations o f  plasma total homocys­
teine in prem enopausal  and  postmenopausal women 
without a history of vascular disease or adverse 
pregnancy outcome, and  to examine a possible rela­
tionship between plasma homocysteine and oestrogen 
status.
Subjects and methods
Subjects
Homocysteine metabolism was studied in 46 preme­
nopausal women (aged 2 7 -4 4  years) and in 26 post­
menopausal wom en (aged 50-60 years), who were 
recruited by public advertisement. Premenopausal 
women were routinely studied approximately 1 week 
before the expected onset of the next menstrual 
period. They were no t  pregnant at the time o f  inves­
tigation. Postm enopausa l  women had reported the 
absence o f  menses for at least 1 year. Their pos t­
menopausal status was confirmed by the measurement 
of  serum follicle-stimulating hormone. All women 
(n =  72) had  delivered at least one liveborn, healthy 
child, and  had  no history o f  (recurrent) spontaneous 
abortion, fetal death, neural  tube defect-affected preg­
nancy, or placental abruption .  They were healthy and 
had not experienced renal, liver or vascular disease. 
Serum creatinine, serum alanine aminotransferase, 
and serum asparta te  aminotransferase were within 
the norm al range. Participants were not allowed to 
take oral contraceptives, horm onal  or vitamin supple­
ments, or any o ther  medication that could possibly 
interfere with homocysteine metabolism for a t  least 3 
m onths  prior  to the study. The study was approved by 
the ethical committee o f  the University Hospital 
Nijmegen St R ad b o u d ,  Nijmegen, the Netherlands. 
W rit ten  informed consent was obtained from all 
women before participation.
Investigation procedure
Homocysteine metabolism was studied by a s tandar­
dized oral methionine loading test as described else­
where [5]. In summary, after an overnight fast venous 
b lood samples were drawn to  measure the concentra­
tions of. plasma homocysteine, serum and red cell 
folate, serum vitamin B12, and whole blood PLP. 
Then, L-methionine, 0T g (O’7 mmol) per kg body 
weight, was administered orally in 200 m L of  orange 
juice. The p lasm a homocysteine concentration was 
measured again 6h  after methionine loading. The 
oestrogen status o f  all participants was assessed on 
the same day by the fasting serum concentration of 
17/3-oestradiol.
Sample preparation and analysis
Blood samples for the quanti ta t ion  of plasma h o m o ­
cysteine were d raw n  in ethylenediamine tetraacetate 
vacutainer tubes o f  4 m L ,  and  centrifuged within
30 min at 3000# for 10 min. The plasma was separated 
and  stored at - 2 0 ° C  until analysis. Total homocys­
teine concentrations were measured by the high-per- 
form ance liquid chrom atography  (HPLC) technique 
with fluorimetric detection, essentially according to 
Fiskerstrand et aL [18]. The lower limit of detection 
was 0*5 /¿molL“ 1; the intra-assay and  interassay coef­
ficients o f  variation were bo th  below 5%. Serum 
concentrations of  17/3-oestradiol were measured 
with a highly specific inhouse radioimmunoassay 
procedure  [19]. The lower limit of detection was 
38 pmol L “ 1. Dry and heparinized vacutainer tubes 
o f  lO m L  were used for collecting venous samples to 
assay the concentrations o f  folate in serum and red 
cells, vitamin B12 in serum, and PL P  in whole blood. 
Folate  and  vitamin B12 concentrations were mea­
sured simultaneously with Dualcount SPB (Solid 
Phase Boil) Radioassay (Diagnostic Products Cor­
pora t ion ,  Los Angeles, CA, USA) [20]. Determination 
o f  P L P  was performed by H P L C  technique [21].
Statistical analysis
Results are given as mean ±  SD. In assessing statis­
tical significance, the Wilcoxon rank sum test and 
S pearm an’s rank correlation were used. P  values were 
two-tailed and P < 0-05 was considered significant.
Results
The m ean  concentrations o f  plasma homocysteine, 
bo th  fasting and after methionine loading, were sig­
nificantly higher in postmenopausal women as com­
pared to premenopausal women (Table 1), Figure 1 
depicts the individual fasting and  postmethionine 
plasma homocysteine concentrations of both groups 
studied.
In  premenopausal women, serum 17/3-oestradiol 
concentrations ranged from 330 to 1500 pmol L“ 1,
Table 1. Concentrations of plasma homocysteine, fasting and after 
methionine loading, serum 17/3-oestradiol and blood vitamins in
premenopausal and postmenopausal women*
Premenopausal Postmenopausal
women n =  46 women n — 26|
Fasting plasma homocysteine 10 i  3 1 2 ± 4 J
(/imol L “ 1)
Postmethionine plasma 32 ± 9 46 ± 16}
homocysteine ( /zm o lL '1)
Serum 17/3-oestradiol 761 ± 284 76 ±  27$
(pmol L-1)
Serum folate (nmol L " 1) 14 ± 4 16 ± 5t
Red cell folate (nmol L ~ ') 513 ± 144 569 ±  159
Serum vitamin B12 285 ± 109 226 ±  85$
(pmol L " 1)
Whole blood PLP (nmol L“ 1) 53 ±  20 46 ± 10
* Values are expressed as mean ±  SD; t/? =  24 in case of serum 
17/3-oestradiol; $ significantly different as compared to premeno­
pausal women, P < 0*05.
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Figure 1. Individual values of plasma homocysteine, fasting ( x ) and 
after methionine loading (A), in premenopausal (/? = 46) and post­
menopausal women (n = 26).
whereas in postmenopausal women these concen­
tra t ions did not exceed 160 pmol L -1 . In two w om en 
o f  the postmenopausal group, serum 17/3-oestradiol 
concentrations were below the detection limit 
(Table 1).
The mean serum and red cell concentrations o f  
folate were higher in postmenopausal women than  
in  premenopausal women, but the difference was only 
significant in the case o f  serum folate (Table 1). M ean  
serum vitamin B12 was significantly lower in pos t­
m enopausal  women than  in premenopausal w om en 
(Table 1). The m ean concentrations of whole blood 
P L P  were not significantly different between groups 
(Table 1).
Table  2 lists the Spearm an’s rank correlation coeffi­
cients between plasma homocysteine, fasting as well 
as after methionine loading, and serum 17/3-oestra­
diol, age, body weight, and blood vitamins in p re ­
m enopausal  and  postmenopausal women. In 
premenopausal women, postmethionine p lasm a 
homocysteine, unlike fasting plasma homocysteine, 
was negatively and  significantly correlated to serum 
17/3-oestradiol (Fig. 2). In postmenopausal women,
n o  significant correlations between plasma hom ocys­
teine and  oestrogen status were found. Neither in 
p rem enopausa l  n o r  in postmenopausal women, fast­
ing and  postmethionine plasma homocysteine were 
significantly correlated to age or body weight, In 
p rem enopausa l  women, bo th  fasting and postmethio­
nine p lasm a homocysteine were negatively and  sig­
nificantly correlated  to serum folate, but not to  the 
o ther  vitamins. In  postmenopausal women, fasting 
p lasm a  homocysteine correlated negatively and  sig­
nificantly to the  vitamins studied, except for PLP, 
whereas postmethionine p lasm a homocysteine was 
negatively and  significantly correlated to serum 
folate, bu t  no t  to  the other vitamins.
Discussion
Plasm a homocysteine, serum 17/3-oestradiol, and 
b lood  vitamin concentrations were studied in 46 
healthy prem enopausal  and  26 healthy postm enopau­
sal women, O u r  results clearly demonstrate tha t  
p lasm a homocysteine concentrations, both fasting 
an d  after methionine loading, are higher in p o s t ­
m enopausa l  w om en  as com pared  to premenopausal 
women. The results of our  study are in agreement with 
those o f  other reports in which homocysteine was 
m easured  either as free disulfides, before as well 
after methionine loading [9,10], or as protein-bound 
homocyst(e)ine in the fasting state [11]. In contrast ,  
A ndersson  et ciL did not find significant differences in 
p lasm a total homocysteine concentrations, either fast­
ing or after methionine loading, relating to m e n o ­
pausal  status [17]. Currently, we have no clear-cut 
explanation for this discrepancy, although some dif­
ferences in subject selection may be of importance.
Several studies have demonstrated a significantly 
positive age-correlation of plasma homocysteine in 
w om en  [11,13,14,16,22]. O ur  results suggest a n  age- 
dependen t  increase of p lasm a homocysteine as welL 
N either  in prem enopausal  nor  in postmenopausal 
w om en, however, was p lasm a homocysteine signifi­
cantly correlated to age, possibly due to the narrow  
ranges o f  age (27 -44  and  50-60  years, respectively). 
Interestingly, K a n g  et al. have reported an ab ru p t  
increase of p lasm a homocysteine among women after 
50 years of age, suggesting a negative relationship 
w ith  ho rm ona l  changes after menopause [11]. Our 
s tudy is p robab ly  the first to  report a significantly 
negative correlation between the concentrations of 
postm eth ionine  plasma homocysteine and serum 
17/3-oestradiol (Table 2, Fig. 2). Remarkably, this 
relationship was found in premenopausal, b u t  not 
in postm enopausal ,  women. We speculate th a t  in 
p rem enopausa l  women, the higher concentrations of 
serum 17/3-oestradiol account in part for the lower 
concentra tions o f  postmethionine plasma hom ocys­
teine, whereas in postm enopausal  women, the range 
o f  serum 17/3-oestradiol is too  small to detect a similar 
relationship. This  view is in line with the observed 
reduction  o f  b lood homocysteine in women during
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Figure 2. Scatter diagram o f postmethionine plasma homocysteine and serum 17/i-oestradiol in premenopausal 
(♦ ;  r =  —0'34, P  <  0*05) and postmenopausal women (■; /• =  0*28, P — 0*18).
pregnancy, a condit ion  which is characterized by a 
high concentra tion  o f  circulating oestrogens [23,24]. 
Additionally, we have recently reported tha t  high 
fasting serum homocysteine concentrations may 
decrease by na tu ra l  oestrogen supplementation after 
menopause [25]. Synthetic oestrogens, like ethinyl- 
oestradiol in oral contraceptives, may affect h o m o ­
cysteine metabolism as well, although da ta  are con­
flicting [21,26].
Serum folate and  serum vitamin B12 are im portant  
determinants o f  fasting plasma homocysteine in 
healthy subjects [15-17], in patients with vascular 
disease [27,28], and  in women with recurrent sponta­
neous abort ion  [5], This is confirmed by the present 
results, except th a t  in premenopausal women the 
concentrations o f  fasting plasma homocysteine were 
no t  correlated to those o f  serum vitamin B12 (Table 
2). In postm enopausal  women, unlike premenopausal
women, fasting plasma homocysteine concentrations 
were negatively and significantly correlated to red cell 
folate concentrations (Table 2). Altogether, these data 
suggest that, in postmenopausal women, 
plasma homocysteine is more dependent on blood 
vitamins as compared to premenopausal women. In 
a recent study of an elderly population aged 67-96 
years, it appeared that  a marginal or manifest vitamin 
deficiency m ay  contribute to two-thirds of the cases of 
high plasma homocysteine [29].
Postmethionine plasma homocysteine was negatively
and significantly correlated to serum folate, both in
premenopausal and  postmenopausal women. This
observation has not been described bv others. How-
0
ever, the increase o f  plasma homocysteine after 
methionine loading and serum folate were reported 
to be not significantly correlated [17,27].
The risk o f  cardiovascular disease in women
Table 2. Correlations between plasma homocysteine, fasting and after methionine loading, and serum I7/?-oestradiol,
age, body weight, and blood vitamins in premenopausal and postmenopausal women*
Premenopausal women n =  46 Postmenopausal women n =  26f
Fasting
plasma
homocysteine
Postmethionine
plasma
homocysteine
Fasting
plasma
homocysteine
Postmethionine
plasma
homocysteine
Serum 17/3-oestradiol -0-06 —0*34} +0*24 +0*28
Age +0-11 -0-05 4-0*07 +0*10
Body weight -0*15 +0*07 +0-01 +0-08
Serum folate - 0 4 3 Î -0*48:1; -0-78J -0*39:1:
Red cell folate +0-07 +0-11 -0*49:1: -0*37
Serum vitamin B12 +0*08 -1-0*07 -0*50:1: -0*08
Whole blood PLP -(-0*03 +0*04 -0*08 +0*03
* Values are Spearman’s rank correlation coefficients; f n  — 24 in case o f  serum 17/3-oestradiol; t  significant corre­
lation, P < 0*05.
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increases rapidly after menopause. Higher concen­
trations of plasma homocysteine are associated with 
a higher risk of cardiovascular disease [4]. Our data 
support the hypothesis that, in women after meno­
pause, the higher concentrations of plasma homocys­
teine contribute to the higher risk o f  cardiovascular 
disease.
It is concluded that plasma homocysteine concen­
trations, both fasting and  after methionine loading, 
are significantly higher in postmenopausal women 
than  in premenopausal women. In premenopausal 
women, the higher concentrations of serum 17/3-oes- 
tradiol may account in part for the lower concen­
trations of postmethionine plasma homocysteine.
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